Phase 1/1b

Redmond, Washington, U.S., September 22, 2026 SystImmune, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...

BOSTON — September 15, 2026 Syntis Bio, Inc. announced results from the 28-day multiple-ascending-dose (MAD) portion of its Phase...